In Q3, Banyan Capital Management Inc. initiated a position in Johnson & Johnson by purchasing 3,853 shares valued at approximately $714,000, making J&J its 22nd largest holding and representing 0.3% of its total portfolio. During the same period, Townsquare Capital LLC reduced its stake by 17.2%, selling 9,801 shares and retaining 47,176 shares worth $8.75 million (1.3% of its holdings). Tandem Investment Advisors Inc. trimmed its position by 2.7%, selling 7,761 shares to finish the quarter with 281,900 shares valued at $52.27 million (1.8% of its portfolio). Meanwhile, Norges Bank added a new stake valued at $4.88 billion in Q2, and Vanguard Group increased its holding by 1.3%, adding 3.09 million shares for a total of 237.05 million shares valued at $36.21 billion. Institutional ownership stands at 69.6% of J&J’s outstanding stock.

The European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive opinion on AKEEGA (niraparib plus abiraterone) for BRCA1/2-mutant metastatic hormone-sensitive prostate cancer, paving the way for a potential new oncology revenue stream. In the U.S., a federal judge dismissed a fraud lawsuit challenging J&J’s talc bankruptcy trust strategy, removing a significant near-term legal overhang. However, legal analysts caution that other talc claims remain unresolved, keeping long-term liability risk under close watch.

Following J&J’s Q4 results—where revenue rose 9.1% year-over-year to $24.56 billion and EPS matched consensus at $2.46—several brokerages raised their targets: Daiwa Capital Markets lifted its target to $237 with an Outperform rating; Scotiabank raised its target to $265 and reiterated Outperform; Morgan Stanley upgraded to Overweight citing stronger growth prospects. Citigroup raised its target from $232 to $250 with a Buy rating, while Goldman Sachs reaffirmed Buy at $250. J&J set FY2026 EPS guidance at 11.43–11.63. The board declared a quarterly dividend of $1.30 per share, marking a 63rd consecutive annual increase and a forward yield of 2.3%.